More than 80% of patients who undergo sentinel lymph node (SLN) biopsy have no nodal metastasis. In this discovery paper, we describe Merlin’s underlying model that combines clinicopathologic and molecular variables to identify patients with thin- and intermediate-thickness melanomas who may forgo the SLN biopsy procedure because of their low risk of nodal metastasis.
About this publication
This paper describes the essentials of Merlin Assay’s underlying CP-GEP algorithm:
Read full article